Baher A. Daihom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Baher A. Daihom has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Alaadin Alayoubi
A Department of Pharmaceutical Sciences , University of Tennessee Health Science Center , Memphis , TN , USA
3 shared publicationsMagdy I. Mohamed
Cairo Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
3 shared publicationsRichard Helms
D Department of Clinical Pharmacy , University of Tennessee Health Science Center , Memphis , TN , USA
3 shared publications- Ahmed Khames
Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
2 shared publications Alia A. Badawi
2 shared publications- Dure Shahwar
Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University Multan, Multan 60800, Pakistan
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14  (21) , 3626
Effect of Chitosan Phonophoresis on Cervical Pain, Disability and Cervical Range of Motion in Smartphone-Addicted Users Aged 16–19 Years: Randomized Controlled Trial
Background and Purpose: Prolonged smartphone use may contribute to cervical pain through sustained muscular overload and increased nociceptive input. This study investigated the effects of adding chitosan phonophoresis to conventional physical therapy on pain, disability, and cervical range of motion (ROM) in smartphone-addicted adolescents with cervical pain. Methods: Thirty-two participants aged 16–19 years with smartphone addiction and cervical pain were randomly assigned to a chitosan phonophoresis group or a control group. Outcomes were assessed before and after treatment using the Neck Disability Index (NDI), Visual Analog Scale for Pain (VAS-P), and cervical range-of-motion (CROM) device. Results: Both groups improved significantly after treatment. Compared with the control group, the chitosan phonophoresis group showed greater reductions in VAS-P (MD = −1.00, 95% CI: −1.59 to −0.41; p = 0.002) and NDI (MD = −3.13, 95% CI: −5.00 to −1.23; p = 0.002). Greater improvements were also observed in cervical ROM, including flexion (MD = 5.63°, 95% CI: 2.58 to 8.67), extension (MD = 6.25°, 95% CI: 1.90 to 10.59), right bending (MD = 3.75°, 95% CI: 1.74 to 5.76), left bending (MD = 4.38°, 95% CI: 1.95 to 6.79), right rotation (MD = 6.25°, 95% CI: 3.70 to 8.80), and left rotation (MD = 6.25°, 95% CI: 3.19 to 9.30; all p < 0.001). Conclusions: Adding chitosan phonophoresis to conventional physical therapy produced greater improvements in cervical pain, disability, and ROM. However, between-group differences in pain and disability were below commonly reported thresholds for clinically important change. Chitosan phonophoresis may be a useful adjunct in managing cervical disorders associated with prolonged smartphone use.
- 26 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14  (21) , 3626
Open AccessEffect of Chitosan Phonophoresis on Cervical Pain, Disability and Cervical Range of Motion in Smartphone-Addicted Users Aged 16–19 Years: Randomized Controlled Trial
Background and Purpose: Prolonged smartphone use may contribute to cervical pain through sustained muscular overload and increased nociceptive input. This study investigated the effects of adding chitosan phonophoresis to conventional physical therapy on pain, disability, and cervical range of motion (ROM) in smartphone-addicted adolescents with cervical pain. Methods: Thirty-two participants aged 16–19 years with smartphone addiction and cervical pain were randomly assigned to a chitosan phonophoresis group or a control group. Outcomes were assessed before and after treatment using the Neck Disability Index (NDI), Visual Analog Scale for Pain (VAS-P), and cervical range-of-motion (CROM) device. Results: Both groups improved significantly after treatment. Compared with the control group, the chitosan phonophoresis group showed greater reductions in VAS-P (MD = −1.00, 95% CI: −1.59 to −0.41; p = 0.002) and NDI (MD = −3.13, 95% CI: −5.00 to −1.23; p = 0.002). Greater improvements were also observed in cervical ROM, including flexion (MD = 5.63°, 95% CI: 2.58 to 8.67), extension (MD = 6.25°, 95% CI: 1.90 to 10.59), right bending (MD = 3.75°, 95% CI: 1.74 to 5.76), left bending (MD = 4.38°, 95% CI: 1.95 to 6.79), right rotation (MD = 6.25°, 95% CI: 3.70 to 8.80), and left rotation (MD = 6.25°, 95% CI: 3.19 to 9.30; all p < 0.001). Conclusions: Adding chitosan phonophoresis to conventional physical therapy produced greater improvements in cervical pain, disability, and ROM. However, between-group differences in pain and disability were below commonly reported thresholds for clinically important change. Chitosan phonophoresis may be a useful adjunct in managing cervical disorders associated with prolonged smartphone use.
- Open Access
- 3 September 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26  (7) , 1-14
3D-printed Gabapentin-loaded Implants for Sustained Release: Leveraging 3D Printing and Hot Melt Extrusion (HME) for Customizable Drug Delivery
Pediatric neuropathy poses significant challenges in pain management due to the limited availability of approved pharmacological options. Gabapentin, commonly used for neuropathic pain, offers therapeutic potential but necessitates careful dosing due to its variable bioavailability. This study investigates the integration of Hot Melt Extrusion and Fused Deposition Modeling in the development of polycaprolactone-based implants for sustained release of Gabapentin. A preliminary screening using Vacuum Compression Molding optimized formulations for Hot Melt Extrusion, enhancing material efficiency and process streamlining. Filaments with a diameter of 1.75 mm were successfully extruded and used for 3D printing of Gabapentin implants. Several tests were undertaken to characterize the prepared filaments and implants. Energy-Dispersive X-ray spectroscopy confirmed the uniform distribution of Gabapentin within the implant matrix. Solid-state characterization techniques were employed to assess the compatibility of implant components and to verify the solid-state of Gabapentin within the implant structure. In vitro drug release studies were conducted. Filaments with varying drug loadings were examined, revealing that a 20% w/w drug loading achieved an optimal balance between rapid and sustained release. Additionally, implants with different infill densities were analyzed, demonstrating that varying infill densities allow control over the amount and percentage of drug released. The 100% infill density resulted in the most sustained release effect, achieving approximately 40% drug release by day 28. These findings underscore the feasibility of 3D printing for producing personalized implants, emphasizing the potential for tailored drug release profiles to meet specific needs of pediatric patients. Graphical Abstract
- 3 September 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26  (7) , 1-14
Open Access3D-printed Gabapentin-loaded Implants for Sustained Release: Leveraging 3D Printing and Hot Melt Extrusion (HME) for Customizable Drug Delivery
Pediatric neuropathy poses significant challenges in pain management due to the limited availability of approved pharmacological options. Gabapentin, commonly used for neuropathic pain, offers therapeutic potential but necessitates careful dosing due to its variable bioavailability. This study investigates the integration of Hot Melt Extrusion and Fused Deposition Modeling in the development of polycaprolactone-based implants for sustained release of Gabapentin. A preliminary screening using Vacuum Compression Molding optimized formulations for Hot Melt Extrusion, enhancing material efficiency and process streamlining. Filaments with a diameter of 1.75 mm were successfully extruded and used for 3D printing of Gabapentin implants. Several tests were undertaken to characterize the prepared filaments and implants. Energy-Dispersive X-ray spectroscopy confirmed the uniform distribution of Gabapentin within the implant matrix. Solid-state characterization techniques were employed to assess the compatibility of implant components and to verify the solid-state of Gabapentin within the implant structure. In vitro drug release studies were conducted. Filaments with varying drug loadings were examined, revealing that a 20% w/w drug loading achieved an optimal balance between rapid and sustained release. Additionally, implants with different infill densities were analyzed, demonstrating that varying infill densities allow control over the amount and percentage of drug released. The 100% infill density resulted in the most sustained release effect, achieving approximately 40% drug release by day 28. These findings underscore the feasibility of 3D printing for producing personalized implants, emphasizing the potential for tailored drug release profiles to meet specific needs of pediatric patients. Graphical Abstract
- Open Access
- 23 June 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17  (7) , 810
Correction: Ameer et al. Treatment of Inflammatory Bowel Disease by Using Curcumin-Containing Self-Microemulsifying Delivery System: Macroscopic and Microscopic Analysis. Pharmaceutics 2024, 16, 1406
- 23 June 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17  (7) , 810
Open AccessCorrection: Ameer et al. Treatment of Inflammatory Bowel Disease by Using Curcumin-Containing Self-Microemulsifying Delivery System: Macroscopic and Microscopic Analysis. Pharmaceutics 2024, 16, 1406
- Open Access
- 31 October 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16  (11) , 1406
Treatment of Inflammatory Bowel Disease by Using Curcumin-Containing Self-Microemulsifying Delivery System: Macroscopic and Microscopic Analysis
Background: The lack of local availability for drugs in the colon can be addressed by preparing a self-microemulsifying drug delivery system (SMEDDS) of curcumin (Cur) which is ultimately used for the treatment of inflammatory bowel disease (IBD). Methods: From preformulation studies, Lauroglycol FCC (oil), Tween 80 (surfactant), Transcutol HP (co-surfactant), and Avicel (solid carrier) were selected for the preparation of blank liquid and solid Cur-loaded SMEDDSs (S-Cur-SMEDDSs). Results: Z-average size (12.36 ± 0.04 nm), zeta potential (−14.7 ± 0.08 mV), and polydispersity index (PDI) (0.155 ± 0.036) showed a comparative droplet surface area and charge of both SMEDDSs. The physicochemical stability of Cur in S-Cur-SMEDDSs was confirmed via FTIR, DSC, TGA, and XRD analyses, while morphological analysis through SEM and atomic force microscopy (AFM) confirmed Cur loading into SMEDDSs with an increased surface roughness root mean square (RMS) of 11.433 ± 0.91 nm, greater than the blank SMEDDS. Acute toxicity studies with an organ weight ratio and % hemolysis of 15.65 ± 1.32% at a high concentration of 600 mM showed that S-Cur-SMEDDSs are safe at a medium dose (0.2–0.8 g/kg/day). The excellent in vitro antioxidant (68.54 ± 1.42%) and anti-inflammatory properties (56.47 ± 1.17%) of S-Cur-SMEDDS proved its therapeutic efficacy for IBD. Finally, S-Cur-SMEDDS significantly improved acetic acid-induced IBD in albino rats through a reduction in the disease activity index (DAI) and macroscopic ulcer score (MUS) from 4.15 ± 0.21 to 1.62 ± 0.12 at 15 mg/kg/day dose, as confirmed via histopathological assay. Conclusions: Based on the above findings, S-Cur-SMEDDS appears to be a stable, less toxic, and more efficacious alternative for Cur delivery with strong competence in treating IBD.
- 31 October 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16  (11) , 1406
Open AccessTreatment of Inflammatory Bowel Disease by Using Curcumin-Containing Self-Microemulsifying Delivery System: Macroscopic and Microscopic Analysis
Background: The lack of local availability for drugs in the colon can be addressed by preparing a self-microemulsifying drug delivery system (SMEDDS) of curcumin (Cur) which is ultimately used for the treatment of inflammatory bowel disease (IBD). Methods: From preformulation studies, Lauroglycol FCC (oil), Tween 80 (surfactant), Transcutol HP (co-surfactant), and Avicel (solid carrier) were selected for the preparation of blank liquid and solid Cur-loaded SMEDDSs (S-Cur-SMEDDSs). Results: Z-average size (12.36 ± 0.04 nm), zeta potential (−14.7 ± 0.08 mV), and polydispersity index (PDI) (0.155 ± 0.036) showed a comparative droplet surface area and charge of both SMEDDSs. The physicochemical stability of Cur in S-Cur-SMEDDSs was confirmed via FTIR, DSC, TGA, and XRD analyses, while morphological analysis through SEM and atomic force microscopy (AFM) confirmed Cur loading into SMEDDSs with an increased surface roughness root mean square (RMS) of 11.433 ± 0.91 nm, greater than the blank SMEDDS. Acute toxicity studies with an organ weight ratio and % hemolysis of 15.65 ± 1.32% at a high concentration of 600 mM showed that S-Cur-SMEDDSs are safe at a medium dose (0.2–0.8 g/kg/day). The excellent in vitro antioxidant (68.54 ± 1.42%) and anti-inflammatory properties (56.47 ± 1.17%) of S-Cur-SMEDDS proved its therapeutic efficacy for IBD. Finally, S-Cur-SMEDDS significantly improved acetic acid-induced IBD in albino rats through a reduction in the disease activity index (DAI) and macroscopic ulcer score (MUS) from 4.15 ± 0.21 to 1.62 ± 0.12 at 15 mg/kg/day dose, as confirmed via histopathological assay. Conclusions: Based on the above findings, S-Cur-SMEDDS appears to be a stable, less toxic, and more efficacious alternative for Cur delivery with strong competence in treating IBD.
- 29 November 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 649, 123652
Unraveling the influence of solvent composition on Drop-on-Demand binder jet 3D printed tablets containing calcium sulfate hemihydrate
- 29 November 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 649, 123652
Unraveling the influence of solvent composition on Drop-on-Demand binder jet 3D printed tablets containing calcium sulfate hemihydrate
- Open Access
- 15 May 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13  (22) , 14943-14957
Novel long-acting brimonidine tartrate loaded-PCL/PVP nanofibers for versatile biomedical applications: fabrication, characterization and antimicrobial evaluation
The global state of antibiotic resistance highlights the necessity for new drugs that can treat a wide range of microbial infections. Drug repurposing has several advantages, including lower costs and improved safety compared to developing a new compound. The aim of the current study is to evaluate the repurposed antimicrobial activity of Brimonidine tartrate (BT), a well-known antiglaucoma drug, and to potentiate its antimicrobial effect by using electrospun nanofibrous scaffolds. BT-loaded nanofibers were fabricated in different drug concentrations (1.5, 3, 6, and 9%) via the electrospinning technique using two biopolymers (PCL and PVP). Then, the prepared nanofibers were characterized by SEM, XRD, FTIR, swelling ratio, and in vitro drug release. Afterward, the antimicrobial activities of the prepared nanofibers were investigated in vitro using different methods against several human pathogens and compared to the free BT. The results showed that all nanofibers were prepared successfully with a smooth surface. The diameters of nanofibers were reduced after loading of BT compared to the unloaded ones. In addition, scaffolds showed controlled-drug release profiles that were maintained for more than 7 days. The in vitro antimicrobial assessments revealed good activities for all scaffolds against most of the investigated human pathogens, particularly the one prepared with 9% BT which showed superiority in the antimicrobial effect over other scaffolds. To conclude, our findings proved the capability of nanofibers in loading BT and improving its repurposed antimicrobial efficacy. Therefore, it could be a promising carrier for BT to be used in combating numerous human pathogens.
- 15 May 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13  (22) , 14943-14957
Open AccessNovel long-acting brimonidine tartrate loaded-PCL/PVP nanofibers for versatile biomedical applications: fabrication, characterization and antimicrobial evaluation
The global state of antibiotic resistance highlights the necessity for new drugs that can treat a wide range of microbial infections. Drug repurposing has several advantages, including lower costs and improved safety compared to developing a new compound. The aim of the current study is to evaluate the repurposed antimicrobial activity of Brimonidine tartrate (BT), a well-known antiglaucoma drug, and to potentiate its antimicrobial effect by using electrospun nanofibrous scaffolds. BT-loaded nanofibers were fabricated in different drug concentrations (1.5, 3, 6, and 9%) via the electrospinning technique using two biopolymers (PCL and PVP). Then, the prepared nanofibers were characterized by SEM, XRD, FTIR, swelling ratio, and in vitro drug release. Afterward, the antimicrobial activities of the prepared nanofibers were investigated in vitro using different methods against several human pathogens and compared to the free BT. The results showed that all nanofibers were prepared successfully with a smooth surface. The diameters of nanofibers were reduced after loading of BT compared to the unloaded ones. In addition, scaffolds showed controlled-drug release profiles that were maintained for more than 7 days. The in vitro antimicrobial assessments revealed good activities for all scaffolds against most of the investigated human pathogens, particularly the one prepared with 9% BT which showed superiority in the antimicrobial effect over other scaffolds. To conclude, our findings proved the capability of nanofibers in loading BT and improving its repurposed antimicrobial efficacy. Therefore, it could be a promising carrier for BT to be used in combating numerous human pathogens.
- 1 November 2022
- Published by Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi
- Vol. 35  (6) , 1481-1493
Dissolution enhancement of olmesartan medoxomil through polymer-based surface solid dispersion and solidified surfactant techniques
This study aims to formulate Olmesartan medoxomil (OM) into oral fast-dissolving tablets (FDTs) to improve its solubility and bioavailability via two different techniques; the polymer-based surface solid dispersion (SSD) technique and the solidified surfactant (SS) technique. In the first technique, two polymers were used; polyvinylpyrrolidone (PVP K90) and Poloxamer 407 (Pluronic@F127), while in the second technique the liquid Tween 80 was solidified by adsorption onto Aeroperl (R) 300. The pre-compression and post-compression parameters of the obtained formulations were assessed. The best formulations were subjected to a taste masking evaluation and a short-term stability study. The results demonstrated that, in comparison to the pure drug, the proportion of drug released from each of the prepared FDTs considerably increased. Results of the stability studies showed that the chosen drug formulations remained stable throughout the storage period.
- 1 November 2022
- Published by Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi
- Vol. 35  (6) , 1481-1493
Dissolution enhancement of olmesartan medoxomil through polymer-based surface solid dispersion and solidified surfactant techniques
This study aims to formulate Olmesartan medoxomil (OM) into oral fast-dissolving tablets (FDTs) to improve its solubility and bioavailability via two different techniques; the polymer-based surface solid dispersion (SSD) technique and the solidified surfactant (SS) technique. In the first technique, two polymers were used; polyvinylpyrrolidone (PVP K90) and Poloxamer 407 (Pluronic@F127), while in the second technique the liquid Tween 80 was solidified by adsorption onto Aeroperl (R) 300. The pre-compression and post-compression parameters of the obtained formulations were assessed. The best formulations were subjected to a taste masking evaluation and a short-term stability study. The results demonstrated that, in comparison to the pure drug, the proportion of drug released from each of the prepared FDTs considerably increased. Results of the stability studies showed that the chosen drug formulations remained stable throughout the storage period.
- 1 August 2020
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 58
Domperidone resinate complex as new formulation for gastroretentive drug delivery
- 1 August 2020
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 58
Domperidone resinate complex as new formulation for gastroretentive drug delivery